Long-term injectable non-insulin antidiabetic drug use and in-hospital mortality in sepsis: A nationwide analysis of the 2023 National Inpatient Sample
Authors' conclusion
Exposure was associated with lower in-hospital mortality, attenuating under stricter comparators. Findings are hypothesis-generating and subject to residual confounding.
Study context
- Population
- Adults with any-listed sepsis and diabeteshospitalizations, 5238 (2.2%) carried Z79.85
- Participants
- 241,808 adults
- Exposure
- Documented long-term injectable non-insulin antidiabetic use vs three pre-specified comparators: the full cohort, therapy-matched, and oral therapy alone
- Z79.85n = 5,238
- Outcome
- In-hospital mortality
Methodological detailssurvey-weighted logistic regression, three pre-specified comparators
- Survey-weighted logistic regression
- Three pre-specified comparators
Main finding
As reported in the abstract
Adjusted odds of death
0.53
95% CI 0.45–0.63
Z79.85 vs full cohort
Adjusted odds of death
0.73
95% CI 0.61–0.87
Z79.85 vs therapy-matched
Adjusted odds of death
0.77
95% CI 0.64–0.93
Z79.85 vs oral therapy alone
Observational data: associations, not effects.
Further findings
Sensitivity to unmeasured confounding
- E-value
- 1.61
Original publication
Long-term injectable non-insulin antidiabetic drug use and in-hospital mortality in sepsis: A nationwide analysis of the 2023 National Inpatient Sample. J Crit Care. Published 8 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →